Entresto

Chemical Namesacubitril/valsartan
Dosage FormTablet (oral; sacubitril mg/ valsartan mg: 24 mg/26 mg, 49 mg/51 mg, 97 mg/103 mg)
Drug ClassInhibitors
SystemCardiovascular
CompanyNovartis
Approval Year2015

Indication

  • To reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure (NYHA Class II-IV) and reduced ejection fraction.
  • For the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older.
Last updated on 10/29/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Entresto (sacubitril and valsartan) Prescribing Information 2019Novartis Pharmaceuticals Corporation, East Hanover, NJ